XML 83 R67.htm IDEA: XBRL DOCUMENT v3.25.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
 1 Months Ended 12 Months Ended
Dec. 29, 2023
Jun. 28, 2023
Feb. 28, 2023
May 17, 2022
Dec. 20, 2018
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Oct. 24, 2023
Interest income           $ 406,449 $ 662,859    
Principal repayments           35,062 27,786    
Outstanding principal balance           $ 4,108,913 $ 4,606,227 $ 5,017,987  
Common stock share issued           23,689,135 15,982,472    
Accounts receivable balance           $ 13,478,263 $ 19,759,254    
Prepaid expenses and other current assets - related party           1,310,388 1,811,911    
Impairment charge           291,980 0    
Revenue           54,426,402 53,376,874    
George Terzis [Member]                  
Unpaid salaries and bonuses           851,000 98,000    
Unpaid salaries and bonuses dues           168,000      
Common stock share issued                 51,485
Grigorios Siokas [Member]                  
Outstanding principal balance           6,194 13,257    
Foreign curreny translation           853 436    
Borrowing         $ 1,718,400        
Interest rate         4.70%        
Maturity date         Mar. 18, 2019        
Cana Holdings Laboratories Holding Limited [Member]                  
Secured promissory note     $ 4,457,520            
Description related to interest on principal     Interest on the Principal Amount under this Note shall accrue at a rate equal to Five Percent (5%) plus one month LIBOR per annum (5.47% as of December 31, 2023)            
Interest income     $ 148,789            
DOC Pharma S.A. [Member]                  
Interest income           203,822      
Principal repayments           310,530      
Interest repayments           $ 125,816      
Interest rate           5.50%      
Loan term           10 years      
Prepayment relates to purchases of inventory           $ 2,600,000      
Maturity date           Dec. 01, 2032      
Accounts payable and accrued expenses - related party           $ 249,768 34,217    
Prepaid balance             4,279,200    
Accounts receivable - related party           2,295,706 2,386,721    
Other expenses               7,599,545  
Prepaid expenses and other current assets - related party           3,284,052 4,347,184    
Cumulative allowance for doubtful accounts           $ 1,400,000      
Agreement terminate           Dec. 31, 2025      
Pieces per product           1,000 pieces      
Purchased of additional licenses           $ 525,461 734,921    
Loan current portion             442,480    
Loan non-current portion           2,898,280 3,539,840    
Impairment charge           160,947      
Revenue           781,386 619,637    
Current portion of Royalty Agreement           362,000      
Non-current portion of Royalty Agreement           1,811,425      
Research and Development costs           517,550      
Inventroy purchase           1,091,540 1,365,324    
Purchase of branded pharmaceuticals $ 3,539,840 $ 1,965,600              
Description of research and development       The total cost of this project will be €1,425,000 plus VAT and will be done over three phases as follows: Design & Development (€725,000); Control and Product Manufacturing (€250,000) and Clinical Study and Research (€450,000). SkyPharm has bought a total of as of 81 licenses at value of €554,500 ($593,204) which is 38.91% of the total cost, as of December 31, 2022          
Monthly basis instalments           35,660      
DOC Pharma S.A. [Member] | Inventories Related Agreement [Member]                  
Inventroy purchase           533,687 1,237,467    
Dimitrios Goulielmos [Member]                  
Outstanding principal balance           10,558 11,283    
Foreign curreny translation           725 371    
Panagiotis Kozaris [Member]                  
Shares owned             51,159 $ 143,056  
Prepaid expenses           194,215 194,215    
Maria Kozari [Member]                  
Accounts receivable balance           1,183,429 1,142,402    
Cumulative allowance for doubtful accounts           735,000      
Net sales           414,443 480,029    
Kanarogloy & Sia Epe [Member]                  
Accounts payable and accrued expenses - related party           15,000      
Basotho Investment Limited [Member]                  
General and administrative expenses           $ 113,300 $ 10,300    
Common stock share issued             120,000